Skip to main content
main-content

ASCO GU 2020

2020 Genitourinary Cancers Symposium coverage

Breaking news and expert interviews from the meeting in San Francisco (February 13–15, 2020).

Expert discussion

25-02-2020 | Renal cell carcinoma | Conference coverage | Video

Treatment options for advanced RCC: Updates from ASCO GU 2020

Axel Merseburger and Laurence Albigès discuss the treatment options for patients with advanced renal cell carcinoma and highlight some of the novel data presented at the 2020 Genitourinary Cancers Symposium that may affect practice in the future.

This independent video was supported by an educational grant from Pfizer and Merck KGaA.

25-02-2020 | Renal cell carcinoma | Conference coverage | Video

Metastatic RCC updates from ASCO GU 2020

Bernard Escudier and Viktor Grünwald take us through the metastatic renal cell carcinoma studies that caught their attention at the 2020 Genitourinary Cancers Symposium, including long-term data from the CheckMate 214 trial and studies of novel agents such as the HIF-2α inhibitor MK-6482 and sitravatinib.

This independent video was supported by an educational grant from Pfizer and Merck KGaA.

Expert interviews

17-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The ATLAS trial

Petros Grivas explains why the story of PARP inhibitors in advanced urothelial carcinoma is not quite finished yet despite the negative results of the ATLAS trial of rucaparib in this setting (4:45).

Read the accompanying news story

17-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The COSMIC-021 mCRPC cohort

Neeraj Agarwal outlines the findings of the metastatic castration-resistant prostate cancer cohort of the COSMIC-021 trial of cabozantinib plus atezolizumab (3:21).

Read the accompanying news story

16-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: Sitravatinib plus nivolumab in advanced RCC

Pavlos Msaouel reports on the efficacy and toxicity of combined treatment with the novel tyrosine kinase inhibitor sitravatinib and nivolumab in people with advanced renal cell carcinoma (4:53).

16-02-2020 | ASCO GU 2020 | Conference coverage | Video

Expert highlights from ASCO GU 2020

Axel Merseburger takes us through the studies that caught his attention at ASCO GU 2020, including the NIMBUS trial and first-in-human study of the HIF-2α inhibitor MK-6482 (3:24).

16-02-2020 | ASCO GU 2020 | Conference coverage | Video

Expert comment: Novel agents in advanced RCC

Daniel Geynisman discusses the potential for the novel tyrosine kinase inhibitor sitravatinib and the HIF-2α inhibitor MK-6482 to change the treatment paradigm in advanced clear-cell renal cell carcinoma (4:47).

16-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: Cytoreductive nephrectomy in the ICI era

Ziad Bakouny presents data on cytoreductive nephrectomy outcomes in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors that suggest there may yet be a role for the procedure in certain patients (4:43).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

Read the accompanying news story

15-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The BLASST-1 trial

Shilpa Gupta gives the top-line results of their trial investigating the addition of nivolumab to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. She also discusses the neoadjuvant NEO-BLADE study presented at the conference and speculates on the reasons for the differing results (3:16).

15-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The RADVAX RCC study

Hans Hammers discusses the RADVAX RCC trial combining dual checkpoint blockade and stereotactic body radiotherapy for the treatment of metastatic renal cell carcinoma, and also comments on the similar NIVES study (2:16).

Read the accompanying news story

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

15-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: HIF-2α inhibition in RCC

Toni Choueiri reports on the advanced renal cell carcinoma cohort of the phase 1/2 trial of MK-6482, a first-in-class inhibitor of hypoxia-inducible factor (HIF)-2α (2:36).

Research news

Reference

ASCO GU 2020 key clinical trial overviews

Read concise summaries of the practice-changing clinical trials being presented at ASCO GU 2020. Highlights include the CHHiP, NIVES, NIMBUS, KEYNOTE-199 and RADVAX RCC trials.

Image Credits